echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Eli Lilly's breast cancer drug Verzenios is recommended by NICE

    Eli Lilly's breast cancer drug Verzenios is recommended by NICE

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    A few days ago, the draft NICE guidelines have recommended Eli Lilly's oral Verzenios (abemaciclib) twice a day for the treatment of hormone receptor-positive, HER2-negative breast cancer in adult patients with breast cancer that has spread to other parts of the body


    In February of this year, the British cost-effectiveness regulator rejected Verzenios' application on the grounds that there was no direct evidence to prove the efficacy of this therapy compared with exemestane combined with everolimus.


    NICE said in a new statement that the newly released positive recommendations for Verzenios were made after Eli Lilly improved the patient access program and provided further economic modeling data


    Verzenios is a CDK4/6 inhibitor that can selectively inhibit cyclin-dependent kinase 4/6 (CDK4/6), restore cell cycle control, and block tumor cell proliferation


    In this regard, Meindert Boysen, director of the NICE Health and Technology Assessment Center, said that advanced breast cancer is an incurable disease, and the purpose of treatment is to delay the deterioration of the disease and prolong survival


    In June last year, Eli Lilly announced the positive results of the Phase III monarchE study of the targeted anticancer drug Verzenio (abemaciclib) for the treatment of breast cancer


    Reference source: NICE recommends Eli Lilly's breast cancer drug Verzenios

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.